Neoadjuvant chemotherapy (NAC), which is defined as chemotherapy administered prior to surgery, is primarily used for patients with locally advanced or inflammatory breast cancer and is also considered in selected early-stage cases with high-risk tumor biology, such as human epidermal growth factor receptor 2 (HER2) enriched or triple-negative subtypes [5]. The gene discussed is ERBB2; the disease is neoplasm.